Vcell Healthcare will obtain the exclusive rights in mainland China to develop, manufacture and commercialize three of Celltrion’s biosimilars, which are approved by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The biosimilars concerned include infliximab biosimilar Remsima (CT P13), rituximab biosimilar Truxima (CT P10) and trastuzumab biosimilar Herzuma (CT P6) [1, 2].

Remsima has, in fact, been commercialized in more than 80 countries worldwide, while Herceptin has also been approved in Japan [3].

Vcell Healthcare aims to launch these products in China as soon as possible, following the regulatory approval process. Celltrion and the Nan Fung Group also intend to explore the opportunity to develop a world-class biologicals manufacturing facility in China.

According to Antony Leung, Chairman and CEO of Nan Fung Group, ‘China has huge unmet medical needs for high quality drugs with affordable prices’. He added that he hopes that ‘Vcell Healthcare Limited could bring world-class biosimilar products to benefit Chinese patients and establish a state of the art manufacturing base in China to serve growing demand for high quality CDMO in the country’.

Related article
Copy biologicals approved in China

References
1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Europe [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2019 Aug 2]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe 
2. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in the US [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2019 Aug 2]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-the-US 
3. GaBI Online - Generics and Biosimilars Initiative. Celltrion wins patent suit in Japan over trastuzumab biosimilar [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2019 Aug 2]. Available from: www.gabionline.net/Biosimilars/General/Celltrion-wins-patent-suit-in-Japan-over-trastuzumab-biosimilar 

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2019 Pro Pharma Communications International. All Rights Reserved.